Meticulous Research® has released a comprehensive report titled “IVD Reagents Market Size, Share, Forecast, & Trends Analysis by Type (Antibodies, Proteins, Oligonucleotides, Nucleic Acid Probes), Technology (Immunoassay, Biochemistry, Microbiology, Hematology), Use (Clinical, RUO), End User - Global Forecast to 2031.” According to the report, the IVD reagents market is expected to reach $79.76 billion by 2031, growing at a CAGR of 5.3% during the forecast period.

Download Sample Research PDF @ https://www.meticulousresearch.com/download-sample-report/cp_id=5110

This market growth is primarily driven by the increasing prevalence of infectious diseases, rising funding for research activities, adoption of advanced diagnostic technologies, and the expansion of proteomics and genomics research. The growing number of clinical laboratories offering advanced diagnostic tests and the rising demand for protein therapeutics and personalized medicine also present significant opportunities for growth. However, stringent regulations for antigen-specific reagents and high reagent costs, along with an unfavorable reimbursement landscape, pose challenges to the market.

Key Players
Prominent players in the IVD reagents market include Thermo Fisher Scientific (U.S.), Becton, Dickinson and Company (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Abcam plc (U.K.), Hologic Inc. (U.S.), and more.

Browse In Depth: https://www.meticulousresearch.com/product/ivd-reagents-market-5110

Market Segmentation and Insights
By Type: The market is categorized into antibodies, purified proteins & peptides, oligonucleotides, nucleic acid probes, and other reagents. In 2024, the antibodies segment is expected to account for the largest share (22.1%) due to their widespread application in research, immunoassay manufacturing, disease diagnosis, and increasing R&D investments.

By Technology: Technological segmentation includes immunoassay/immunochemistry, biochemistry/clinical chemistry, molecular diagnostics, microbiology, hematology, coagulation/hemostasis, urinalysis, and other IVD technologies. The immunoassay/immunochemistry segment is projected to dominate the market in 2024, holding 30.8% of the market share, driven by the preference for immunodiagnostic tests due to their high accuracy, specificity, and sensitivity.

By Use: The market is segmented into clinical use, research use only (RUO), and analyte-specific reagents (ASR). The clinical use segment is anticipated to account for the largest share in 2024, driven by the growing need for early detection of infectious diseases and the large volume of clinical test samples.

By End User: End users of IVD reagents include IVD manufacturers, reference laboratories, academic institutes & research laboratories, and hospital laboratories. The IVD manufacturers segment is expected to hold the largest share (35%) of the market in 2024, due to increased focus on collaborations and product launches.

Quick Buy – IVD Reagents Market – Global Opportunity Analysis and Industry Forecast (2024-2031), Research Report: https://www.meticulousresearch.com/Checkout/21348226

Geographic Analysis
Geographically, North America is projected to dominate the IVD reagents market in 2024 with a 37.7% share, driven by its advanced healthcare infrastructure and the presence of key players like Thermo Fisher Scientific (U.S.) and Becton, Dickinson and Company (U.S.). Europe and Asia-Pacific are also key regions contributing to the market’s growth, with the U.S. leading in North America.

Contact Us:
Meticulous Research®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research